Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Cytokinetics (Nasdaq: CYTK) announced inducement equity awards granted on January 15, 2026 to eight new employees hired in December 2025 and January 2026. The company granted options to purchase 29,416 shares and 19,825 restricted stock units (RSUs) that will settle in common stock upon vesting.

The RSUs vest over 3 years (40% at year 1, 40% at year 2, 20% at year 3). The options vest over 4 years (25% at year 1, then monthly over 36 months), carry a $63.44 exercise price (equal to the closing price on January 15, 2026) and have a 10-year term. Awards are subject to the company's equity plan and Nasdaq Listing Rule 5635(c)(4).

News Market Reaction – CYTK

-1.16%

1 alert

-1.16% News Effect

On the day this news was published, CYTK declined 1.16%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Stock options granted: 29,416 options RSUs granted: 19,825 RSUs Employees granted: 8 employees +5 more

8 metrics

Stock options granted 29,416 options Inducement awards to 8 new employees on Jan 15, 2026

RSUs granted 19,825 RSUs Inducement awards to 8 new employees on Jan 15, 2026

Employees granted 8 employees New hires starting December 2025 and January 2026

Option exercise price $63.44 per share Equal to CYTK closing price on Jan 15, 2026

Option term 10 years Term of inducement stock options granted Jan 15, 2026

RSU vesting schedule 40% / 40% / 20% Annual vesting over 3 years, subject to continued service

Option vesting period 4 years 25% at 1 year then monthly over 36 months

Pre-news share price $62.58 Latest close before inducement grant announcement

Market Reality Check

Price: $60.06 Vol: Volume 1,225,555 is below...

low vol

$60.06 Last Close

Volume Volume 1,225,555 is below the 20-day average of 2,212,578 (0.55x activity). low

Technical Price $62.58 is trading above the 200-day MA at $47.17.

Peers on Argus

CYTK was down 1.35% while close peers were mixed: AXSM up 0.89%, LEGN down 0.83%...

1 Up

CYTK was down 1.35% while close peers were mixed: AXSM up 0.89%, LEGN down 0.83%, ABVX roughly flat to modestly negative in sector snapshot but appeared in momentum scanning up about 4%. No evidence of a broad, aligned sector move.

Historical Context

5 past events · Latest: Jan 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 05	Conference presentation	Neutral	+5.5%	J.P. Morgan Healthcare Conference presentation and webcast details.
Dec 19	FDA approval	Positive	+4.6%	FDA approval of MYQORZO for symptomatic obstructive hypertrophic cardiomyopathy.
Dec 17	China approval	Positive	-3.5%	NMPA approval in China with milestone payment and future milestone eligibility.
Dec 16	Inducement grants	Neutral	-0.2%	Equity inducement awards to new employees under Nasdaq Rule 5635(c)(4).
Dec 12	EU opinion	Positive	+4.3%	Positive CHMP opinion supporting EU marketing authorization for MYQORZO.

Pattern Detected

Recent major regulatory events (FDA and CHMP approvals) tended to see positive price alignment, while one China approval/milestone headline saw a negative reaction.

Recent Company History

Over the past few months, Cytokinetics reported several key milestones. A Dec 12, 2025 positive CHMP opinion for MYQORZO was followed by a 4.25% gain, and U.S. FDA approval on Dec 19, 2025 saw shares rise 4.59%. China’s NMPA approval and milestone on Dec 17, 2025 coincided with a -3.55% move, showing one divergence from generally positive reactions to good news. Routine items such as inducement grants and a conference presentation in Dec 2025–Jan 2026 produced relatively modest moves.

Market Pulse Summary

This announcement details routine inducement equity awards—29,416 stock options and 19,825 RSUs—to 8...

Analysis

This announcement details routine inducement equity awards—29,416 stock options and 19,825 RSUs—to 8 new employees under Nasdaq Listing Rule 5635(c)(4). The structure mirrors the prior Dec 16, 2025 inducement grants, with options priced at recent market levels and vesting over 3–4 years. In context of recent major milestones, including FDA and CHMP decisions for MYQORZO, this filing is primarily administrative, and investors may focus more on upcoming regulatory and commercial execution metrics.

Key Terms

restricted stock units, Nasdaq Listing Rule 5635(c)(4), stock options, equity incentive plan

4 terms

restricted stock units financial

"and 19,825 restricted stock units (RSUs) that will be settled in shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Nasdaq Listing Rule 5635(c)(4) regulatory

"material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

stock options financial

"it granted stock options to purchase an aggregate of 29,416 shares"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

equity incentive plan financial

"subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 15, 2026 it granted stock options to purchase an aggregate of 29,416 shares of common stock and 19,825 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 8 employees, whose employment commenced in December 2025 and January 2026 as a material inducement to their employment.

The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in each case, subject to each respective employee’s continued service with the Company. The stock options that were granted are subject to an exercise price of $63.44 per share, which is equal to the closing price of the Company’s common stock on January 15, 2026 and will vest over 4 years, with 1/4^th of the shares underlying the employee’s option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting in monthly installments at a rate of 1/48^th of the shares underlying such stock options over the subsequent 36 months, subject to each respective employee’s continued service with the Company. The stock options have a 10-year term. These awards are subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan and the applicable award agreements pursuant to which the awards were granted.

The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO™ (aficamten) is a cardiac myosin inhibitor approved for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms by the U.S. Food and Drug Administration and the China National Medical Products Administration. The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending marketing authorization in the European Union for MYQORZO® (aficamten) with a decision expected from the European Commission in first quarter in 2026. Aficamten is also being studied for the potential treatment of non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission particularly under the caption “Risk Factors” in Cytokinetics’ latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

FAQ

What equity awards did Cytokinetics (CYTK) grant on January 15, 2026?

Cytokinetics granted options to purchase 29,416 shares and 19,825 RSUs to eight new employees as inducements to employment.

What is the vesting schedule for the CYTK RSUs granted in January 2026?

The RSUs vest over 3 years: 40% at year 1, 40% at year 2, and 20% at year 3, subject to continued service.

What are the terms and exercise price for the CYTK stock options granted January 15, 2026?

Options vest over 4 years (25% at year 1, then monthly over 36 months), have a $63.44 exercise price and a 10-year term.

Why were the CYTK stock options and RSUs granted under Nasdaq Listing Rule 5635(c)(4)?

The awards were granted as material inducements to employment, which is permitted under Nasdaq Listing Rule 5635(c)(4).

How many employees received inducement awards from Cytokinetics in January 2026?

A total of 8 employees who began employment in December 2025 and January 2026 received the inducement awards.